TY  - JOUR
AU  - Zimmermann, Noah
AU  - Kött, Julian
AU  - Zell, Tim
AU  - Abedini, Ali Zeinal
AU  - Blomen, Chiara L
AU  - Belz, Stella
AU  - Deitert, Benjamin
AU  - Heidrich, Isabel
AU  - Geidel, Glenn
AU  - Rünger, Alessandra
AU  - Smit, Daniel J
AU  - Weichenthal, Michael
AU  - Ugurel, Selma
AU  - Leiter, Ulrike
AU  - Berking, Carola
AU  - Gutzmer, Ralf
AU  - Schadendorf, Dirk
AU  - von Wasielewski, Imke
AU  - Mohr, Peter
AU  - Meier, Friedegund
AU  - Herbst, Rudolf
AU  - Utikal, Jochen
AU  - Terheyden, Patrick
AU  - Haferkamp, Sebastian
AU  - Pföhler, Claudia
AU  - Kaatz, Martin
AU  - Ziller, Fabian
AU  - Ulrich, Jens
AU  - Meiss, Frank
AU  - Bauer, Alexander T
AU  - Schneider, Stefan W
AU  - Gebhardt, Christoffer
TI  - Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.
JO  - European journal of cancer
VL  - 234
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-03059
SP  - 116195
PY  - 2026
N1  - 2025 Dec 19:234:116195 / Available online 19 December 2025
AB  - Targeted therapies (TT) improve outcomes in BRAF-mutant melanoma. Pre-clinical data suggest that anticoagulation (AC) and platelet aggregation inhibition (PAI) may have antitumoral effects. We evaluated the impact of concomitant AC or PAI on outcomes in patients receiving TT.We analyzed 1296 patients with unresectable stage III-IV BRAF-mutant melanoma treated with BRAF plus MEK inhibitors (2016-2024) in the prospective multicenter ADOReg registry. Patients were categorized as receiving no antithrombotic therapy (ATT; n = 1125), PAI (n = 73; acetylsalicylic acid or clopidogrel), or AC (n = 98; direct oral anticoagulants, low-molecular-weight heparin, or vitamin K antagonists).Median follow-up was 1.3 years. Compared with patients without ATT, those receiving AC had significantly improved 12-month progression-free survival (PFS; HR 0.55, 95 
KW  - Anticoagulation (Other)
KW  - Melanoma (Other)
KW  - Targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41448065
DO  - DOI:10.1016/j.ejca.2025.116195
UR  - https://inrepo02.dkfz.de/record/307460
ER  -